ReviewAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2017
The Real Role of β-Blockers in Daily Cardiovascular Therapy.
Review in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- A 7-point evidence-based care discharge protocol for patients hospitalized for exacerbation of COPD: consensus strategy and expert recommendation.NPJ primary care respiratory medicine · 2024Pooled it
- Pooled it
- Moderate dose of dietary nitrate improves skeletal muscle microvascular function in patients with peripheral artery disease.Microvascular research · 2023Trial
- Body mass-normalized moderate dose of dietary nitrate intake improves endothelial function and walking capacity in patients with peripheral artery disease.American journal of physiology. Regulatory, integrative and comparative physiology · 2021Trial
- The prognostic impact of beta blockers in ischemic heart failure: time for a paradigm shift?Heart failure reviews · 2026Review
- Towards sustainable pharmaceutical QC: micellar-UPLC strategy for concomitant analysis of a cardiovascular polypill with aniline and salicylic acid impurities.Scientific reports · 2026Article
- Beta-Blockers and mortality in patients with malignancy and cardiovascular disease: an analysis of the MIMIC-IV database.BMC cancer · 2025Article
- Review
- Impact of Genetic Variation in Adrenergic Receptors on β-Blocker Effectiveness and Safety in Cardiovascular Disease Management: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Evaluation of a Specialist Nurse-Led Post-Coronary Heart Disease Support Program: A Prospective Pre-Post Interventional Study.Healthcare (Basel, Switzerland) · 2024Article
- Association between comorbid COPD or chronic bronchitis and the prognosis of patients with Dilated cardiomyopathy.Annals of medicine · 2024Article
- Review
- Beta-Blockers of Different Generations: Features of Influence on the Disturbances of Myocardial Energy Metabolism in Doxorubicin-Induced Chronic Heart Failure in Rats.Biomedicines · 2024Article
- Nonadherence to Cardiovascular Drugs Predicts Risk for Non-Arthritic Anterior Ischemic Optic Neuropathy: A Large-Scale National Study.Journal of clinical medicine · 2024Article
- Biomorphometric and hematobiochemical alterations in the juvenile african catfish Clarias gariepinus exposed to propranolol.BMC zoology · 2024Article
- Prevalence of cardiovascular drug-related adverse drug reactions consultations in UK primary care: A cross-sectional study.PloS one · 2024Article
- Traditional Therapeutics and Potential Epidrugs for CVD: Why Not Both?Life (Basel, Switzerland) · 2023Review
- Systemic hypertension in adults with congenital heart diseases.International journal of cardiology. Congenital heart disease · 2023Review
- Longitudinal Assessment of Multimorbidity Medication Patterns among Smokers in the COPDGene Cohort.Medicina (Kaunas, Lithuania) · 2023Article
- Role of β-blockers in Preventing Heart Failure and Major Adverse Cardiac Events Post Myocardial Infarction.Current cardiology reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of β-adrenoceptor antagonists (β-blockers) in cardiovascular therapy has been subject to diverse trends and changes over the decades. With the advent of a wide variety of excellent drugs for the treatment of antihypertension, β-blockers have been relegated from the first-line treatment of essential hypertension. However, they remain the drugs of first choice in recommendations from the respective medical societies for heart failure, coronary artery disease, and atrial fibrillation as well as in hypertension complicated with heart failure, angina pectoris, or prior myocardial infarction. When indicated, cardioselective β-blockers should be prescribed in patients with diabetes mellitus or chronic obstructive pulmonary disease. We review the available evidence for the use of β-blockers in clinical conditions in which recommendations can be made for everyday practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.